Velcura names new board member

Prior to joining Velcura, Mr Brinkerhoff served as COO of Cerenis Therapeutics, which discovers, develops and commercializes breakthrough high-density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases.

Mr Brinkerhoff, a graduate of the University of Michigan, earned his MBA with distinction in 1989. Mr Brinkerhoff also has bachelor’s and master’s degrees in industrial engineering and operations research from U-M’s College of Engineering.

Mr Brinkerhoff said: “In joining Velcura’s board, I look forward to assisting them in their mission of developing therapies that restore bone health.”